Anticipated to be an enormous deal, Alzheimer’s drug is pulled after disappointing gross sales : NPR

MARY LOUISE KELLY, HOST:

A drugmaker is pulling the plug on an Alzheimer’s remedy that was as soon as anticipated to be a blockbuster. NPR’s Sydney Lupkin studies on what occurred and what it may imply for sufferers.

SYDNEY LUPKIN, BYLINE: Aduhelm was presupposed to be an enormous deal. That is as a result of the drug cleared sticky clumps of protein referred to as amyloid from the brains of sufferers with Alzheimer’s illness. Of the 2 massive research of Aduhelm submitted to the Meals and Drug Administration, one discovered that the drug delayed the lack of reminiscence and pondering, whereas the opposite discovered no clear profit. A panel of consultants advising the company advisable in opposition to approval, however the company did it anyway in 2021 with a catch. Biogen, the drug’s maker, needed to do extra analysis to substantiate Aduhelm labored and get the examine carried out by 2030. Now Biogen says it could not discover a accomplice or financing to assist pay for the pricey confirmatory examine, so it is slicing its losses and specializing in its different FDA-approved Alzheimer’s drug referred to as Leqembi. Dr. Aaron Kesselheim from Harvard was one in all three FDA advisers who resigned in protest over the Aduhelm approval.

AARON KESSELHEIM: The truth that within the intervening three-plus years that there was no extra knowledge that is come out that recommended something constructive about this drug is an indicator to me that the advisory committee was right in assessing this drug didn’t have good proof and shouldn’t have been authorized.

LUPKIN: Aduhelm by no means took off. Biogen initially set its value at $56,000 a yr, however demand was so weak the corporate slashed the worth in half a number of months later. Medicare additionally restricted protection for Aduhelm to sufferers who had been in medical trials. Nonetheless, Biogen’s resolution to withdraw Aduhelm was surprising. Heather Snyder from the Alzheimer’s Affiliation says sufferers had been nonetheless being enrolled within the confirmatory examine when Biogen made its announcement. However she says there is a silver lining.

HEATHER SNYDER: The approval of Aduhelm was a landmark occasion that actually supplied hope for thus many people which can be or had been dwelling with early Alzheimer’s and their households.

LUPKIN: And different experimental Alzheimer’s medication are shifting ahead within the pipeline. Biogen says sufferers at present taking Aduhelm may have entry to it till November 1, however sufferers taking the drug in medical trials will lose entry Might 1. Biogen had licensed the drug from a Swiss biotech referred to as Neurimmune. Neurimmune says it would proceed to work on the drug and goals to hunt approval for a model that’s given by injection as a substitute of infusion.

Sydney Lupkin, NPR Information.

(SOUNDBITE OF MUSIC)

Copyright © 2024 NPR. All rights reserved. Go to our web site phrases of use and permissions pages at www.npr.org for additional info.

NPR transcripts are created on a rush deadline by an NPR contractor. This textual content might not be in its remaining type and could also be up to date or revised sooner or later. Accuracy and availability could range. The authoritative report of NPR’s programming is the audio report.